Dr. Monroe accepts director position at FDA

Overall, Black men were 24% less likely to receive or be prescribed a novel hormonal therapy agent compared with White men.

In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.

In the third article of this series, Paul E. Dato, MD, provides comprehensive insights on the multidisciplinary care of patients with metastatic castration-resistant prostate cancer.

"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.

“Our experience with TULSA demonstrates substantial post-procedure decreases in PSA level, PSA density, and prostate volume,” the researchers wrote.

Small index lesions on initial multiparametric MRI were linked to a less aggressive clinical course for patients with prostate cancer on active surveillance.